Jean-Luc Labourey
Overview
Explore the profile of Jean-Luc Labourey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fumet J, Roussot N, Bertaut A, Limagne E, Thibaudin M, Hervieu A, et al.
Future Oncol
. 2024 Nov;
20(38):3077-3085.
PMID: 39530624
Trifluridine/tipiracil-bevacizumab is a standard of care in metastatic colorectal cancer (mCRC) after chemotherapy failure. We aim to assess the addition of XB2001 (anti-IL-1 alpha monoclonal antibody) plus trifluridine/tipiracil-bevacizumab in mCRC...
2.
Orlando V, Drubay D, Lavaud P, Faivre L, Lesaunier F, Delva R, et al.
Clin Genitourin Cancer
. 2023 Jun;
21(5):615.e1-615.e8.
PMID: 37263910
Introduction: Serum prostate specific antigen (PSA) is a well-known prognostic parameter in men with prostate cancer. The treatment of men with very high PSA values and apparently no detectable metastases...
3.
Barlesi F, Dixmier A, Debieuvre D, Raspaud C, Auliac J, Benoit N, et al.
Oncoimmunology
. 2021 Jan;
9(1):1744898.
PMID: 33457089
EVIDENS is an ongoing, prospective, non-interventional study evaluating the effectiveness and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). Adults with a pathologically confirmed diagnosis of lung...
4.
Bouche O, Abdelghani M, Labourey J, Triby S, Bensadoun R, Jouary T, et al.
World J Gastroenterol
. 2019 Aug;
25(29):4007-4018.
PMID: 31413534
Background: Anti-epidermal growth factor receptor therapy is associated with skin adverse events not previously reported with conventional chemotherapy. Prophylactic actions are recommended, but routine clinical management of these toxicities and...
5.
Lamure S, Carles C, Aquereburu Q, Quittet P, Tchernonog E, Paul F, et al.
JAMA Netw Open
. 2019 Apr;
2(4):e192093.
PMID: 31002318
Importance: Professional use of pesticides is a risk factor for non-Hodgkin lymphoma. The main biological mechanisms of pesticides and chemotherapy are genotoxicity and reactive oxygen species generation. Cellular adaptation among...
6.
Nahon S, Rastkhah M, Abdelghani M, Soumoudronga R, Gasnereau I, Labourey J
Support Care Cancer
. 2015 Oct;
24(5):1991-1998.
PMID: 26507190
Purpose: Chemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer treatment. Prophylactic treatment with granulocyte-colony stimulating factor (G-CSF) decreases the incidence of febrile neutropenia, the rate of hospitalization,...
7.
Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, et al.
Lancet Oncol
. 2015 Jun;
16(7):787-94.
PMID: 26028518
Background: Early risk-stratified chemotherapy is a standard treatment for breast, colorectal, and lung cancers, but not for high-risk localised prostate cancer. Combined docetaxel and estramustine improves survival in patients with...
8.
Gravis G, Boher J, Fizazi K, Joly F, Priou F, Marino P, et al.
Eur Urol
. 2014 Oct;
68(2):196-204.
PMID: 25277272
Background: The Glass model developed in 2003 uses prognostic factors for noncastrate metastatic prostate cancer (NCMPC) to define subgroups with good, intermediate, and poor prognosis. Objective: To validate NCMPC risk...
9.
Michallet M, Luporsi E, Soubeyran P, Amar N, Boulanger V, Carreiro M, et al.
BMC Cancer
. 2014 Jul;
14:503.
PMID: 25011615
Background: The approval of epoetin biosimilars in the European Union requires extensive scientific evaluation and stringent regulatory procedures, including post-marketing studies. The ORHEO (place of biOsimilaRs in the therapeutic management...
10.
Fizazi K, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, et al.
Eur J Cancer
. 2011 Nov;
48(2):209-17.
PMID: 22119204
Aim: To assess docetaxel-estramustine in patients with localised high-risk prostate cancer. Patients And Methods: After staging pelvic lymph node dissection, patients with high-risk prostate cancer randomly received androgen deprivation therapy...